Kyverna Therapeutics, Inc.
Moat Score — Kyverna Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Kyverna holds an exclusive NIH license to the foundational CD19 CAR technology and nine distinct patent families, with method-of-treatment protection on miv-cel extending to 2042-2044, but the core underlying CAR science is also available to oncology-focused competitors under different licenses, limiting exclusivity. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Autologous CAR T manufacturing is inherently expensive and patient-specific; Kyverna relies on external manufacturing partners and has no demonstrated cost advantage versus other cell-therapy developers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved product yet, Kyverna has no current pricing power, though CAR T therapies in oncology have historically commanded very high one-time prices, suggesting meaningful future pricing potential if miv-cel is approved. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Cell therapy manufacturing and treatment exhibit no network effects; value depends on clinical data and manufacturing execution, not on the number of other patients or sites using the therapy. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Because miv-cel is designed as a one-time infusion rather than a chronic therapy, there is no traditional recurring-switching-cost dynamic; any stickiness would come from durable remission outcomes rather than patient lock-in. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Autoimmune CAR T is a nascent, highly specialized niche requiring exclusive licensing and complex manufacturing partnerships that raise the bar for new entrants, but Cabaletta Bio and Cartesian Therapeutics are both already pursuing the same space, limiting how much efficient-scale protection exists. |